Last reviewed 2026-04-20 · How we verify

Metiazic Acid (METIAZINIC ACID)

Phase 2 active Small molecule

Metiazic Acid (generic name: METIAZINIC ACID) is a drug. It is currently in Phase 2 development.

Metiazic Acid works by binding to a specific target in the body, altering its function to produce a therapeutic effect.

Metiazic Acid is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Metiazic Acid are also unknown. As a small molecule, it is likely to be administered orally, but its pharmacokinetic properties such as half-life and bioavailability are not documented. Further research is needed to understand its mechanism of action and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METIAZINIC ACID
Target	Prostaglandin G/H synthase 2
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a city with many different buildings. Metiazic Acid is like a key that unlocks a specific building, allowing it to work differently to help the city function better. This is a simplified explanation of how Metiazic Acid works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Metiazic Acid CI brief — competitive landscape report
Metiazic Acid updates RSS · CI watch RSS

Frequently asked questions about Metiazic Acid

What is Metiazic Acid?

Metiazic Acid (METIAZINIC ACID) is a Small molecule drug.

How does Metiazic Acid work?

Metiazic Acid works by binding to a specific target in the body, altering its function to produce a therapeutic effect.

What is the generic name of Metiazic Acid?

METIAZINIC ACID is the generic (nonproprietary) name of Metiazic Acid.

What development phase is Metiazic Acid in?

Metiazic Acid is in Phase 2.

What does Metiazic Acid target?

Metiazic Acid targets Prostaglandin G/H synthase 2.

Target: All drugs targeting Prostaglandin G/H synthase 2
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing